Veracyte, Inc. or Taro Pharmaceutical Industries Ltd.: Who Leads in Yearly Revenue?

Veracyte's Revenue Growth: A Rising Challenge to Taro's Dominance

__timestampTaro Pharmaceutical Industries Ltd.Veracyte, Inc.
Wednesday, January 1, 201475928500038190000
Thursday, January 1, 201586294400049503000
Friday, January 1, 201695075100065085000
Sunday, January 1, 201787938700071953000
Monday, January 1, 201866191300092008000
Tuesday, January 1, 2019669893000120368000
Wednesday, January 1, 2020644769000117483000
Friday, January 1, 2021548970000219514000
Saturday, January 1, 2022561347000296536000
Sunday, January 1, 2023572952000361051000
Monday, January 1, 2024629182000
Loading chart...

Unleashing insights

A Tale of Two Companies: Veracyte, Inc. vs. Taro Pharmaceutical Industries Ltd.

In the competitive landscape of the pharmaceutical and biotechnology sectors, revenue growth is a key indicator of success. Over the past decade, Taro Pharmaceutical Industries Ltd. has consistently outperformed Veracyte, Inc. in terms of annual revenue. However, the gap is narrowing. In 2014, Taro's revenue was nearly 20 times that of Veracyte. Fast forward to 2023, and Veracyte's revenue has surged to approximately 63% of Taro's, showcasing a remarkable growth trajectory.

While Taro's revenue peaked in 2016, Veracyte has shown a steady upward trend, particularly from 2019 onwards, with a significant leap in 2021. This shift highlights Veracyte's strategic advancements and market penetration. As we look to the future, the question remains: will Veracyte continue its upward climb and eventually surpass Taro, or will Taro maintain its lead?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025